Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Fahad Abdulaziz Alsayed"'
Autor:
Saad Saleh Aldughaythir, Yousef Alolah, Mohsen Alzahrani, Fahad Abdulaziz Alsayed, Bader Muaykil Alqahtani, Omar Abdulrahman Alhathlol
Publikováno v:
Journal of Applied Hematology, Vol 8, Iss 4, Pp 140-144 (2017)
CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treatment and outcome has improved dramatically from the average survival of 3–5 years in the past to almost normal life expectancy with the new targeted
Externí odkaz:
https://doaj.org/article/75ed14bbb40e4f458a818072f82dbd8b
Autor:
Emad Masuadi, Ali Alaklabi, Abdullah Bin Shabib, Sumayyah Al Tamimi, Azzam Alotaibi, Saad Saleh Aldughaythir, Hanan Habeeb, Mosaad Almegren, Fahad Abdulaziz Alsayed, Mohsen Alzahrani, Rajkumar Rajendram
Publikováno v:
Annals of Thoracic Medicine, Vol 13, Iss 2, Pp 108-113 (2018)
Annals of Thoracic Medicine
Annals of Thoracic Medicine
BACKGROUND: Inferior vena cava (IVC) filter is indicated in patients with acute venous thromboembolism (VTE) in whom therapeutic anticoagulation is contraindicated. While prophylactic insertion of an IVC filter may be considered for patients at high
Autor:
Fahad Abdulaziz Alsayed, Saad Saleh Aldughaythir, Yousef Alolah, Bader Muaykil Alqahtani, Mohsen Alzahrani, Omar Abdulrahman Alhathlol
Publikováno v:
Journal of Applied Hematology, Vol 8, Iss 4, Pp 140-144 (2017)
CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treatment and outcome has improved dramatically from the average survival of 3–5 years in the past to almost normal life expectancy with the new targeted